Evidence map›Paper›PMID 26379965›Full record

ArticleInternational journal of clinical and experimental medicine2015

Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients.

Fayth L Miles, Jian-Yu Rao, Curtis Eckhert, Shen-Chih Chang, Allan Pantuck, Zuo-Feng Zhang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Determination ofDisease markers · 2019
    Article
  3. Association ofOncology letters · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fayth L MilesDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles Los Angeles, CA, USA.
Jian-Yu RaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA Los Angeles, CA, USA.
Curtis EckhertDepartment of Environmental Health Sciences, Fielding School of Public Health, University of California-Los Angeles Los Angeles, CA, USA.
Shen-Chih ChangDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles Los Angeles, CA, USA.
Allan PantuckDepartment of Urology, David Geffen School of Medicine at UCLA Los Angeles, CA, USA.
Zuo-Feng ZhangDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles Los Angeles, CA, USA ; Jonsson Comprehensive Cancer Center, University of California-Los Angeles Los Angeles, CA, USA.
Los Angeles County Department of Public Health · USUniversity of California, Los Angeles · US

Funding

UCLA CANCER EPIDEMIOLOGY TRAINING PROGRAMT32CA009142 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHANG, ZUO-FENG · 1986 to 2024
$6.3M
NCI NIH HHS T32 CA009142
6 · The paper itself

Abstract

The progression of prostate cancer is influenced by systemic inflammation, and may be attributed, in part, to genetic predisposition. Single nucleotide polymorphisms associated with the immune response may help mediate prostate cancer progression. We analyzed data from a hospital-based case-control study of 164 prostate cancer patients and 157 healthy male controls from the Memorial Sloan Kettering Cancer Center. We evaluated associations between six immunity-related polymorphisms (CRP rs1205 and rs1800947, FGFR2 rs1219648 and rs2981582, IFNGR1 rs11914, and IL10 rs1800871) and overall survival among prostate cancer patients, calculating adjusted hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards regression. FGFR2 rs1219648 (GG vs. AA) and rs2981582 (TT vs. CC) polymorphisms were associated with more favorable overall survival (HR: 0.13, 95% CI: 0.03-0.62 and HR: 0.13, 95% CI: 0.03-0.53, respectively) in patients with primary prostate cancer. These observations highlight the need to validate and identify these and other immunity-related polymorphisms in larger studies examining survival of prostate cancer patients.

Indexed as

case-controlGenetic predispositionimmune responsepolymorphismsproportional hazards modelprostate cancer

Identifiers

PMID26379965
PMCPMC4565348
OpenAlexW2397283849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.